甲状腺癌患者131I诱导唾液腺损伤的危险因素
本研究纳入216例甲状腺癌患者,通过问卷和病历调查口干症与唾液腺炎症状,并在1507例患者数据库中回顾性验证。结果显示,131I治疗与口干症和唾液腺炎发生率升高相关;口干症患者平均累积131I活度较无口干症者高46 mCi,平均首次给药活度高21 mCi;年龄增大与口干症发生率升高相关,女性唾液腺炎发生率更高;131I治疗前有唾液腺炎病史者治疗后唾液腺炎发生率更高;131I治疗患者中诊断AID-SS者口干症和唾液腺炎发生率更高。结论认为131I诱导唾液腺损伤的危险因素包括给药活度、年龄、性别、131I治疗前唾液腺炎病史及AID-SS诊断。
要点
- 口干症患者平均累积131I活度较无口干症者高46 mCi,平均首次给药活度高21 mCi。
- 年龄增大与口干症发生率升高相关,女性唾液腺炎发生率更高。
- 131I治疗前有唾液腺炎病史者治疗后唾液腺炎发生率更高。
核心结论
- 131I诱导唾液腺损伤的危险因素包括给药131I活度、年龄、性别、131I治疗前唾液腺炎病史及AID-SS诊断。
研究设计与样本
- 纳入2013年4月至2014年4月期间就诊于The Ohio State University Wexner Medical Center的216例甲状腺癌患者,通过问卷和病历检索识别口干症和唾液腺炎症状。
- 在现有数据库(n=1507)中回顾性检索唾液腺炎、口干症及与Sjögren综合征相关的自身免疫病(AID-SS)的ICD-9/10代码以验证发现。
- 从病历中提取人口学和临床信息,进行多变量分析以识别唾液腺损伤的独立预测因素。
主要发现
- 131I治疗与口干症和唾液腺炎发生率升高相关。
- 口干症患者平均累积131I活度较无口干症者高46 mCi,平均首次给药131I活度较无口干症者高21 mCi。
- 年龄增大与口干症发生率升高相关,女性唾液腺炎发生率更高。
- 131I治疗前有唾液腺炎病史者,131I治疗后唾液腺炎发生率更高。
- 131I治疗患者中诊断AID-SS者(无论诊断在131I治疗前或后),口干症和唾液腺炎发生率更高。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
CONTEXT: Sialadenitis and xerostomia are major adverse effects of 131I therapy in thyroid cancer patients. The risk factors for these adverse effects, other than administered activity of 131I, have not been investigated. OBJECTIVE: The aim of this study is to identify risk factors for 131I-induced salivary gland damage among follicular cell-derived thyroid cancer patients. DESIGN: We enrolled 216 thyroid cancer patients who visited The Ohio State University Wexner Medical Center between April 2013 and April 2014. Symptoms of xerostomia and sialadenitis were identified via questionnaire and medical record search. To validate the findings in a large cohort, we retrospectively searched for ICD-9/10 codes for sialadenitis, xerostomia, and autoimmune disease associated with Sjögren's syndrome (AID-SS) in our existing database (n = 1507). Demographic and clinical information was extracted from medical records. Multivariate analyses were performed to identify independent predictors for salivary gland damage. RESULTS: 131I treatment associated with higher incidence of xerostomia and sialadenitis. Patients with xerostomia had 46 mCi higher mean cumulative 131I activity and 21 mCi higher mean first-administered 131I activity than patients without xerostomia. Increased age associated with higher incidence of xerostomia, and females had a higher incidence of sialadenitis. Patients who experienced sialadenitis before 131I therapy had higher sialadenitis incidence after 131I therapy. 131I-treated patients diagnosed with AID-SS, whether before or after 131I treatment, had a higher incidence of xerostomia and sialadenitis among 131I-treated patients. CONCLUSION: Risk factors for 131I-induced salivary gland damage include administered 131I activity, age, gender, history of sialadenitis before 131I treatment, and AID-SS diagnosis.
引用
- Hollingsworth B, Senter L, Zhang X, et al. Risk Factors of 131I-Induced Salivary Gland Damage in Thyroid Cancer Patients. J Clin Endocrinol Metab. 2016. PMID: 27533304
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。